Niagen Bioscience, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
NAGE$2.15-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 8. Financial Statements and Supplementary Data
| Index to Consolidated Financial Statements | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 173) | 48 |
| Consolidated Balance Sheets at December 31, 2025 and December 31, 2024 | 49 |
| Consolidated Statements of Operations for the Years Ended December 31, 2025 and December 31, 2024 | 50 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2025 and December 31, 2024 | 51 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and December 31, 2024 | 52 |
| Notes to Consolidated Financial Statements | 53 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.